Healthcare | May 05, 2026
OBESITAS 2026 concludes with focus on India’s rising obesity burden
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Patients can now get the starting 2.5 mg dose for $299 per month
Subscribe To Our Newsletter & Stay Updated
